✦ LIBER ✦

Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck. A southwest oncology group study

✍ Scribed by Maha Hussain; Jacqueline Benedetti; Roy E. Smith; Gladys I. Rodriguez; David Schuller; John Ensley

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 456 KB
Volume: 76
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19951001)76:7<1233::aid-cncr2820760721>3.0.co;2-q

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of low dose continuous infusi

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study

✍ Julie A. Kish; Michael Wolf; E. David Crawford; Joseph T. Leimert; Anton Buesche 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 2 views

Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil(5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology

Infusional interleukin-2 and 5-fluoroura

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma : A Southwest Oncology Group Phase II study

✍ Laurence Elias; Danika Lew; Robert A. Figlin; Robert C. Flanigan; Mark E. Thomps 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 1 views

Final report of a phase II evaluation of

Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck : An Eastern Cooperative Oncology Group trial (PA390)

✍ Arlene A. Forastiere; Darleen Shank; Donna Neuberg; Samuel G. Taylor IV; Ronald 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.